Antitumor Efficacy of CC Motif Chemokine Ligand 19 in Colorectal Cancer

Digestive Diseases and Sciences

Volumn 59, Issue 9, 2014, Pages 2153-2162

  Lu, Jun ^a   Zhao, Jingkun ^a   Feng, Hao ^b   Wang, Puxiongzhi ^a   Zhang, Zhuo ^a   Zong, Yaping ^a   Ma, Junjun ^a   Zheng, Minhua ^a   Lu, Aiguo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angiogenesis; CCR7; Cell invasion; Cell migration; Cell proliferation; Chemokine CCL19; Receptors

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CHOLECYSTOKININ OCTAPEPTIDE; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; SMALL INTERFERING RNA;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CACO 2 CELL LINE; CANCER STAGING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; LOVO CELL LINE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SW116 CELL LINE; SW620 CELL LINE; TISSUE MICROARRAY; TUMOR LOCALIZATION; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL;

AGED; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL19; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; GENE SILENCING; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CCR7; RECOMBINANT PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR BURDEN;

EID: 84907873981     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3138-y     Document Type: Article

References (20)

1. Myers EA, Feingold DL, Forde KA, Arnell T, Jang JH, Whelan RL. Colorectal cancer in patients under 50 years of age: a retrospective analysis of two institutions’ experience. World J Gastroenterol. 2013;19:5651–5657.
2. Réaux-Le Goazigo A, Van Steenwinckel J, Rostène W, Mélik Parsadaniantz S. Current status of chemokines in the adult CNS. Prog Neurobiol. 2013;104:67–92.
3. Guerreiro R, Santos-Costa Q, Azevedo-Pereira JM. The chemokines and their receptors: characteristics and physiological functions. Acta Med Port. 2011;24:967–976.
4. Wolf M, Albrecht S, Märki C. Proteolytic processing of chemokines: implications in physiological and pathological conditions. Int J Biochem Cell Biol. 2008;40:1185–1198.
5. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–292.
6. Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110:20212–20217.
7. Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012;150:165–178.
8. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T (reg) cells. Nature. 2011;475:226–230.
9. Wang W, Huang P, Zhang L, et al. Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo. Cancer Sci. 2013;104:1523–1531.
10. Antonicelli F, Lorin J, Kurdykowski S, et al. CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo. Br J Dermatol. 2011;164:720–728.
11. Polimeno M, Napolitano M, Costantini S, et al. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. Bju Int. 2013;112:686–696.
12. Franciszkiewicz K, Boissonnas A, Boutet M, Combadiere C, Mami-Chouaib F. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res. 2012;72:6325–6332.
13. Ngo VN, Tang HL, Cyster JG. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells. J Exp Med. 1998;188:181–191.
14. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med. 1998;188:373–386.
15. Hou T, Liang D, Xu L, Huang X, Huang Y, Zhang Y. Atypical chemokine receptors predict lymph node metastasis and prognosis in patients with cervical squamous cell cancer. Gynecol Oncol. 2013;130:181–187.
16. Zhang Q, Sun L, Yin L, et al. CCL19/CCR7 upregulates heparanase via specificity protein-1 (Sp1) to promote invasion of cell in lung cancer. Tumour Biol. 2013;34:2703–2708.
17. Hamanishi J, Mandai M, Matsumura N, et al. Activated local immunity by CC chemokine ligand 19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer. Stem Cells. 2010;28:164–173.
18. Westermann J, Nguyen-Hoai T, Baldenhofer G, et al. CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther. 2007;14:523–532.
19. Itakura M, Terashima Y, Shingyoji M, et al. High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients. Br J Cancer. 2013;109:1100–1108.
20. Yates-Binder CC, Rodgers M, Jaynes J, Wells A, Bodnar RJ, Turner T. An IP-10 (CXCL10)-derived peptide inhibits angiogenesis. PLoS ONE. 2012;7:e40812.